Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves’ disease and type 1 diabetes mellitus: A case report

Rituximab (RTX) is a monoclonal antibody that targets the B-cell-specific CD20 antigen. Recent reports indicate that RTX is effective against type 1 diabetes mellitus (T1DM) and hematologic as well as autoimmune diseases. Other studies have indicated that RTX therapy leads to the remission of recurr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrine Journal 2015, Vol.62(1), pp.69-75
Hauptverfasser:	Kurozumi, Akira, Okada, Yosuke, Arao, Tadashi, Narisawa, Manabu, Torimoto, Keiichi, Yamamoto, Sunao, Tanaka, Yoshiya
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antigens, CD20 - chemistry Autoantibodies - analysis Autoantibodies - chemistry Autoimmune polyglandular syndrome Diabetes Mellitus, Type 1 - etiology Diabetes Mellitus, Type 1 - prevention & control Graves Disease - etiology Graves Disease - prevention & control Graves’ disease Humans Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Japan Male Polyendocrinopathies, Autoimmune - drug therapy Polyendocrinopathies, Autoimmune - ethnology Polyendocrinopathies, Autoimmune - immunology Polyendocrinopathies, Autoimmune - physiopathology Receptors, Thyrotropin - antagonists & inhibitors Remission Induction Rituximab Rituximab - adverse effects Rituximab - therapeutic use Thyroid Gland - drug effects Thyroid Gland - physiopathology Thyroid Gland - secretion Type 1 diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!